Temoporfin is a photosensitizing agent used in the treatment of squamous cell carcinoma of the head and neck . It was first authorized for market by the European Medicines Agency in October 2001. It is currently available under the brand name Foscan.
For use in the treatment of patients with advanced squamous cell carcinoma of the head and neck failing standard therapies and who are unsuitable for radiotherapy, surgery, or systemic chemotherapy .
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.